The reversal of fortunes for Gilead Sciences' Trodelvy in an advanced form of breast cancer is complete, with an FDA approval unlocking what could be a sizeable new market
Menarini subsidiary Stemline Therapeutics has won FDA approval for Orserdu, the first in a new class of oral selective oestrogen receptor degrader (SERD) drugs that provide a new form
